Combined targeting of PRDX6 and GSTP1 as a potential differentiation strategy for neuroblastoma treatment

Abstract excerpt

Neuroblastoma (NB) is a heterogeneous childhood cancer, characterized by the amplification of the MYCN oncogene in 40% of the high-risk cases. Our previous work demonstrated that MYCN drives metabolic reprogramming in NB, including upregulation of antioxidant enzymes. Here, we identify peroxiredoxin 6 (PRDX6) as a promising therapeutic target in NB. Pharmacological inhibition of PRDX6 reduces MYCN levels, induces...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ATP Synthase and ATPases Research
• Share to Mitochondrial Function and Pathology
• Share to Neuroblastoma Research and Treatments